Effects of ReclastOne way to assess the severity of Paget's disease is by measuring the level of alkaline phosphate in the blood. In studies, Reclast was shown to decrease alkaline phosphate levels, which indicates that it helps to improve Paget's disease. Studies compared a single dose of Reclast with daily doses of Actonel® (risedronate) 30 mg, a similar medication used to treat Paget's disease. Up to 89 percent of people who took Reclast achieved normal alkaline phosphate levels, compared to just 58 percent of those taking Actonel. In addition, Reclast seemed to work more quickly than Actonel.
Reclast has also been studied for osteoporosis in postmenopausal women. Studies showed that one dose of Reclast per year reduces the risk of vertebral (spine) fractures, hip fractures, and fractures in general, compared to a placebo injection (an injection with no active ingredient). Both groups of women were also given vitamin D and calcium supplements. These studies also showed that Reclast can prevent the loss of height that can occur in people with osteoporosis.
Studies have also shown that Reclast can increase bone mineral density in postmenopausal women with low bone mass (that are at a high risk for developing osteoporosis).
Additionally, studies have shown that Reclast can increase bone mineral density in men with osteoporosis. Also, one study compared Reclast with oral bisphosphonate medication for treating and preventing osteoporosis due to glucocorticoid steroids (such as prednisone). This study showed that Reclast was superior for increasing bone mineral density.